- Motley Fool•11 hours ago
Johnson & Johnson, Amgen, and Gilead Sciences currently rank as the most cash-rich drugmakers -- but Pfizer could knock one of them out of its spot soon.
- Barrons.com•11 hours ago
Wells Fargo Securities We are tracking data from BrandImpact survey to gauge treatment trend and market share shifts among the different therapies for multiple myeloma (MM). In February, Celgene’s (CELG) Revlimid and Johnson & Johnson (JNJ)/Takeda’s Velcade held overall market shares of 48% and 33%, respectively. JNJ’s Darzalex overall share rose slightly to 6%, driven by about 300 basis-point share increase to 11% in second line and rebound from 20% to 30% share in third line+.
U.S. Democratic Senator Claire McCaskill sought on Tuesday details from the nation's top opioid drugmakers on their sales and marketing practices, as lawmakers step up efforts to tackle the country's deadly opioid crisis. The Missouri senator's investigation comes amid an epidemic of opioid addiction, with 91 Americans dying everyday as a result of overdose, according to the U.S. Centers for Disease Control and Prevention. "This epidemic is the direct result of a calculated sales and marketing strategy major opioid manufacturers have allegedly pursued over the past 20 years to expand their market share," McCaskill, the top Democrat on the Senate Homeland Security and Governmental Affairs Committee, wrote in a letter to the drugmakers.
JNJ : Summary for Johnson & Johnson Common Stock - Yahoo Finance
Johnson & Johnson (JNJ)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||124.36 - 125.33|
|52 Week Range||107.69 - 129.00|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||21.06|
|Dividend & Yield||3.20 (2.54%)|
|1y Target Est||N/A|